Clearside Biomedical Faces Analyst Downgrades Amid Strategic Review

Clearside Biomedical shares are trading lower after multiple firms, including Needham and Stifel, downgraded the stock following the company's announcement to explore strategic alternatives. Stifel reduced its price target from $8 to $2.